Longaeva Partners’s Abivax ABVX Stock Holding History

Longaeva Partners’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-32,886	Closed	-$2.79M	–	121
2025 Q3	$2.79M	Buy	+32,886	New	+$2.02M	0.4%	43

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Longaeva Partners's ABVX Position: Q4 2025 in Review

Longaeva Partners sold out of Abivax (ABVX) in Q4 2025, closing a stake of 32,886 shares — an estimated $2.79M sold.

Longaeva Partners first reported a position in ABVX in Q3 2025 and held it in 1 quarter. The position peaked at $2.79M in Q3 2025. 247 funds tracked by Wall St. Rank hold ABVX as of Q4 2025.

Longaeva Partners reported no remaining Abivax position as of Q4 2025 after selling out during the quarter.
Longaeva Partners sold 32,886 Abivax shares in Q4 2025, an estimated $2.79M.
Longaeva Partners first reported a position in Abivax in Q3 2025 and held it in 1 quarter.
Longaeva Partners's Abivax position peaked at $2.79M in Q3 2025.
247 funds tracked by Wall St. Rank held Abivax as of Q4 2025.

Based on Longaeva Partners's 13F filing for Q4 2025, filed 17 Feb 2026.